A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 4 WEEKS IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Trial Profile

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED 2-WAY CROSSOVER STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF PF-03715455 ADMINISTERED TWICE DAILY BY INHALATION FOR 4 WEEKS IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs PF 3715455 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 09 Jun 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 14 May 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 06 Apr 2015 Planned number of patients changed from 80 to 100 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top